|
[1] BABA
T，HOUKIN K，KURODA S. Novel epidemiological
features of Moyamoya disease[J]. J Neurol Neurosurg Psychiatry，2008，79（8）：900-904.
[2] YIM
S H，CHO C B，JOO W I，et al. Prevalence and epidemiological features of Moyamoya disease
in Korea[J]. J Cerebrovasc Endovasc Neurosurg，2012，14（2）：75-78.
[3] KAMADA
F，AOKI Y，NARISAWA A，et al. A genome-wide association study identifies RNF213 as the
first Moyamoya disease gene[J]. J Hum Genet，2011，56（1）：34-40.
[4] IHARA
M，YAMAMOTO Y，HATTORI Y，et al. Moyamoya disease：diagnosis and
interventions[J]. Lancet Neurol，2022，21（8）：747-758.
[5] MERTENS
R，GRAUPERA M，GERHARDT H，et al. The genetic basis of Moyamoya disease[J]. Transl Stroke Res，2022，13（1）：25-45.
[6] ALTMüLLER J，PALMER L J，FISCHER
G，et al. Genomewide scans of complex human diseases：true linkage is hard to find[J]. Am J Hum Genet，2001，69（5）：936-950.
[7] DUAN
L，WEI L，TIAN Y H，et al. Novel susceptibility loci for Moyamoya disease revealed by a
genome-wide association study[J]. Stroke，2018，49（1）：11-18.
[8] AHN
I M，PARK D H，HANN H J，et al. Incidence，prevalence，and survival of Moyamoya disease in Korea：a
nationwide，population-based study[J]. Stroke，2014，45（4）：1090-1095.
[9] KURIYAMA
S，KUSAKA Y，FUJIMURA M，et al. Prevalence and clinicoepidemiological features of Moyamoya
disease in Japan：findings from a nationwide
epidemiological survey[J]. Stroke，2008，39（1）：42-47.
[10] HAN
D H，KWON O K，BYUN B J，et al. A co-operative study：clinical
characteristics of 334 Korean patients with Moyamoya disease treated at
neurosurgical institutes（1976—1994）[J]. Acta Neurochir（Wien），2000，142（11）：1263-1264.
[11] HAN
C，FENG H，HAN Y Q，et al. Prospective screening of family members with Moyamoya disease
patients[J/OL]. PLoS One，2014，9（2）：e88765[2024-01-01]. https://doi.org/10.1371/journal.pone.0088765.
[12] FUJIMURA
M，TOMINAGA T，KURODA S，et al. 2021 Japanese guidelines for the management of Moyamoya
disease：guidelines from the Research Committee on
Moyamoya Disease and Japan Stroke Society[J]. Neurol Med Chir（Tokyo），2022，62（4）：165-170.
[13] HE
S H，DUAN R，LIU Z Q，et al. Characteristics of cognitive impairment in adult asymptomatic
Moyamoya disease[J/OL]. BMC Neurol，2020，20（1）：322[2024-01-01].
https://doi.org/10.1186/s12883-020-01898-8.
[14] HE
S H，LIU Z Q，WEI Y C，et al. Impairments in brain perfusion，executive
control network，topological characteristics，and neurocognition in adult patients with asymptomatic Moyamoya
disease[J/OL]. BMC Neurosci，2021，22（1）：35[2024-01-01].
https://doi.org/10.1186/s12868-021-00638-z.
[15] 段炼. 烟雾病诊断、治疗及发病原因的思考[J]. 中国卒中杂志，2008，3（7）：470-471.
DUAN
L. Diagnosis，treatment and etiology of Moyamoya
disease[J]. Chin J Stroke，2008，3（7）：470-471.
[16] FEGHALI
J，XU R S，YANG W Y，et al. Moyamoya disease versus Moyamoya syndrome：comparison of presentation and outcome in 338 hemispheres[J]. J
Neurosurg，2019，133（5）：1441-1449.
[17] MIYAMOTO
S，YOSHIMOTO T，HASHIMOTO N，et al. Effects of
extracranial-intracranial bypass for patients with hemorrhagic Moyamoya disease：results of the Japan adult Moyamoya trial[J]. Stroke，2014，45（5）：1415-1421. |
